Andexxa/Ondexxya

Andexxa/Ondexxya

Andexxa/Ondexxya

Andexanet alfa

200 mg lyophilized powder in single-use vials

Alexion Pharmaceuticals, Inc/Portola Pharmaceuticals UK Ltd.

Medical Use

Andexanet alfa (known as Andexxa in the U.S. and Ondexxya in the EU) is a recombinant modified human factor Xa (FXa) protein. It is used to stop life-threatening or uncontrolled bleeding in adults who are taking direct FXa inhibitors or anticoagulants, specifically apixaban or rivaroxaban.

Dosage Recommendations: Andexanet alfa should be administered intravenously using a 0.2 or 0.22-micron in-line polyethersulfone or low protein-binding filter. The recommended dosages are:

  • -Low Dose: An initial IV bolus of 400 mg at a target rate of 30 mg/min, followed by a continuous infusion of 4 mg/min for up to 120 minutes.
  • -High Dose: An initial IV bolus of 800 mg at a target rate of 30 mg/min, followed by a continuous infusion of 8 mg/min for up to 120 minutes.